Lupin's Indian Formulations business continues to witness exemplary growth, where the Company continues to outpace and outperform the Indian Pharmaceutical Market (IPM). During FY 2008-09, Lupin's domestic Formulations business recorded sales of Rs. 11,412 Mn, as compared to Rs. Rs. 9,496 Mn (FY 2008-09), registering a growth of over 20% which was twice that of the IPM, which grew at just 10% (ORG IMS Mar 09). The Company continues to gain wide market acceptance, with most of its flagship products being market leaders in their respective segments. Six of Lupin's products are amongst the top 300 brands in the country. Riding high on gains made during the year, Lupin improved its ranking to No. 5 in the IPM (ORG IMS Mar 09), moving up one notch from No. 6 in FY 2007-08. The Company today is the fastest growing company amongst the top 5 in the IPM, with an overall market share of 2.73%. (ORG IMS Mar 09)
Strategic Approach
Lupin has several strategic marketing arms that focus on specific therapy segments. This approach provides impetus to the business through enhanced relationships with the doctors and better market penetration. The success of this model is reflected in the growing market share of Lupin in the domestic market. With undivided focus on the niche areas, the Company has successfully built a strong brand value amidst the medical community. | 
